• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

This uterine fibroid treatment is underused despite being cost-effective

March 13, 2017 By Danielle Kirsh

Fibroids within the Uterus
[Image from the U.S. Department of Health and Human Services]
A new study suggests that a minimally invasive, image-guided treatment for uterine fibroids is used a lot less than other surgical treatments.

Hysterectomies were performed 65 times more than the minimally invasive uterine fibroid embolization (UFE), which has even been proven to cost less and result in a shorter hospital stay.

“These findings suggest there is a lack of awareness about this safe, effective and less invasive therapy for uterine fibroids,” Dr. Prasoon Mohan, the study’s lead author, said in a press release. “Interventional radiologists urge healthcare professionals to present patients with all available treatment options so that the patient can make an informed decision. Patients need to know about the major differences between surgical treatments and UFE, especially that this is a non-surgical treatment that preserves the uterus and has a much faster recovery time compared to a hysterectomy.”

Get the full story on our sister site, Medical Design & Outsourcing.

Filed Under: Women's Health Tagged With: medtech, uterine fibroid embolization, uterine fibroids

IN CASE YOU MISSED IT

  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM
  • Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan
  • Abbott sets Libre Duo glucose-ketone sensor US launch for December
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS